A Case of LGI1 Encephalitis Presenting with NORSE
Archives of Epilepsy, cilt.30, sa.1, ss.36-38, 2024 (ESCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 1
- Basım Tarihi: 2024
- Doi Numarası: 10.4274/archepilepsy.2023.23093
- Dergi Adı: Archives of Epilepsy
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
- Sayfa Sayıları: ss.36-38
- Anahtar Kelimeler: Antibody, autoimmune, encephalitis, leucine-rich glioma-inactivated 1, LGI1, neuroimmunology, neurology, norse, status epilepticus
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
New-onset refractory status epilepticus (NORSE) is a rare, life-threatening clinical presentation in patients without a known history of epileptic seizures. Autoimmune encephalitis is the most common cause identified in adults; however, in up to 50% of cases, no cause can be found. We present a case of a previously healthy 26-year-old male admitted to the intensive care medicine with NORSE, whose condition improved with the initiation of immunotherapy. Later, he was diagnosed with anti-leucine-rich glioma-inactivated 1 (anti-LGI1) antibody encephalitis. Despite prompt initiation of immunotherapy, cognitive function deterioration and resistant seizures persisted. NORSE is a critical condition that requires urgent treatment. In patients with a negative initial work-up, a preliminary diagnosis of autoimmune encephalitis should be considered. It is critical to begin immunotherapy before the autoimmune encephalitis panel results, as early treatment improves outcomes and long-term prognosis.